Lupin rose 1.65% to Rs 785.70 after the global pharma major announced that the company is launching Merzee capsules, 1 mg/ 20 mcg, in the U.S. market, under exclusive license, marketing and distribution agreement with Slayback Pharma LLC.
Slayback Pharma LLC (Slayback) had earlier launched this product in the US in February 2021. Merzee (Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules), 1 mg/20 mcg, a generic equivalent of Taytulla (Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules), 1 mg/ 20 mcg of Allergan Pharmaceuticals International.
Merzee is an oral estrogen/ progestin combination oral contraceptive (COC) used by women to prevent pregnancy. One capsule is taken daily in order as provided in the blister pack.
As per IQVIA MAT February 2022, Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg (RLD: Taytulla) had estimated annual sales of $90 million in the U.S.
Lupin is a transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The company's consolidated net profit jumped 24.47% to Rs 545.52 crore on a 3.57% rise in total revenue from operations to Rs 4,160.93 crore in Q3 FY22 over Q3 FY21.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU